1
|
Dreyling MH, Leppa S, Comeau T, Kosinova M, Lenz G, Nagler A, Heo DS, Oh SY, Huang L, Wirtz O, Miriyala A, Garcia-Vargas JE, Childs BH, Zinzani PL. Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.7570] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Martin H. Dreyling
- Klinikum der Universität München LMU, Medizinische Klinik und Poliklinik III, Munich, Germany
| | - Sirpa Leppa
- Helsinki University Central Hospital Cancer Center, Helsinki, Finland
| | | | - Marina Kosinova
- Kemerovo Region Regional Clinical Hospital, Kemerovo, Russia
| | - Georg Lenz
- Translational Oncology Medical Clinic, Münster University Clinic, Münster, Germany
| | - Arnon Nagler
- Chaim Sheba Medical Center-Tel Aviv University, Tel-Hashomer, Israel
| | - Dae Seog Heo
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
| | - Sung Yong Oh
- Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea, Republic of (South)
| | - Liping Huang
- Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ
| | - Oliver Wirtz
- Bayer AG, Pharmaceuticals Division, Wuppertal, Germany
| | | | | | | | - Pier Luigi Zinzani
- Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy
| |
Collapse
|
2
|
Keating KN, Hiemeyer F, Garcia-Vargas JE, Childs BH, Dreyling MH, Zinzani PL. Patient-reported outcomes from a phase 2 study of copanlisib in patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (iNHL). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e18123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e18123 Background: Information on the degree to which treatment of iNHL impacts health-related quality of life in terms of disease- and treatment-related symptoms is limited. Copanlisib is an investigational pan-Class I phosphatidylinositol 3-kinase (PI3K) inhibitor. In a phase II study in patients with relapsed/refractory iNHL, copanlisib treatment resulted in a high response rate and durable responses. We report here on patient-reported outcomes (PRO) from this trial (NCT01660451, part B). Methods: Patients with 4 subtypes of iNHL were eligible: follicular, marginal zone, small lymphocytic and lymphoplasmacytoid/Waldenstrӧm macroglobulinemia. Patients had to have received ≥2 prior lines of treatment, including rituximab and an alkylating agent. Copanlisib (60 mg, I.V.) was intermittently administered on days 1, 8 and 15 of a 28-day cycle. Health-related quality of life questionnaire FACT-Lym questionnaire (with focus on Total and Lymphoma subscale [FACT-LymS] and LOCF-method applied) was evaluated with Hodges-Lehmann estimate for change in median until week 16, including 95% confidence intervals. EQ-5D and visual analogue scale (EQ-5D VAS) were statistically described. All questionnaires were compiled at baseline and every other cycle in the first year of the study (aligned with radiological imaging). Results: A total of 141 iNHL patients were treated, with completed questionnaires received from 132 patients at baseline and 86 at week 16. The mean±SD (and median) for FACT-Lym LymS score at baseline was 45.27 ± 9.55 (46.5), and 47.20 ± 8.69 (49.0) at 16 weeks. The estimated change in median was +1.0 with 95% CI: [0.5; 2.5] and min: -13.0, max: 23.0, representing an improvement in lymphoma-related symptoms. Accordingly, the FACT-Lym total score was 126.59 ± 22.96 (127.5) at baseline and 127.99 ± 23.60 (130.8) at 16 weeks. Estimated change in median was 0.0 with 95% CI: [-0.5; 3.2] and min: -38.0, max 42.5. Conclusions: This study demonstrated the favorable impact of copanlisib treatment on disease-related symptoms and HRQoL in patients with relapsed/refractory iNHL.
Collapse
Affiliation(s)
| | | | | | | | | | - Pier Luigi Zinzani
- Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy
| |
Collapse
|
3
|
Dreyling MH, Santoro A, Leppa S, Demeter J, Follows G, Lenz G, Kim WS, Mollica L, Nagler A, Diong CP, Provencio M, Stevens DA, Trevarthen D, Magagnoli M, Cupit L, Yin S, Hiemeyer F, Garcia-Vargas JE, Childs BH, Zinzani PL. Copanlisib in patients with relapsed or refractory follicular lymphoma. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.7535] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7535 Background: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (iNHL) subtype, yet treatment options in the relapsed/refractory (r/r) setting are limited. Copanlisib is a pan-Class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant PI3K-α and PI3K-δ activity. We report results from the FL subset of a large phase II study (n=141) in iNHL patients (pts) (NCT01660451, part B). Methods: A total of 104 pts with indolent FL (grade 1-3a) relapsed/refractory to ≥2 prior lines of treatment were treated with copanlisib (60 mg IV infusion) administered on days 1, 8 and 15 of a 28-day cycle. The primary endpoint was objective tumor response rate (ORR) per independent radiologic review (Cheson et al., JCO 20:579, 2007). Results: Of the 104 pts treated, 62% were refractory; median prior lines 3 (range 2-8), median time from progression 8 wks (range 1-73 wks). 52% were male, 83% white, median age 62 yrs, and 62% ECOG 0. At the time of primary analysis the ORR was 58.7%, comprising 15 pts (14.4%) with complete response (CR) and 46 (44.2%) with partial response. Stable disease was observed in 35 (33.7%) pts and progression of disease as best response in 2 pts. The median duration of response was 370 days (range 0-687), with 43 responders censored at data cut-off. Median duration of treatment was 22 wks (range 1-105); 33 (32%) pts remained on treatment. For all pts, the most common treatment-emergent AEs occurring in >25% of pts included (all grade/grade 3+): diarrhea (34%/5%), reduced neutrophil count (30%/24%), fatigue (30%/2%), and fever (25%/4%). Hyperglycemia (50%/41%) and hypertension (30%/24%) were transient. The incidence of pneumonitis (8%/1.4%), hepatic enzymopathy (AST 28%/1.4%; ALT 23%/1.4%), opportunistic infection (1.4%) and colitis (0.7%) were low. Six deaths were observed, 3 of which were attributed to copanlisib: one lung infection, one respiratory failure, and one thromboembolic event. Conclusions: Copanlisib was highly active as a single agent in heavily pretreated r/r FL pts and resulted in durable responses in the majority of pts. Toxicities were manageable, with a low incidence of severe AEs associated with other PI3K inhibitors, especially hepatic enzymopathy, opportunistic infections, and colitis. Clinical trial information: NCT01660451.
Collapse
Affiliation(s)
| | - Armando Santoro
- Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - Sirpa Leppa
- Helsinki University Central Hospital Cancer Center, Helsinki, Finland
| | - Judit Demeter
- Semmelweis University, First Department of Internal Medicine, Division of Haematology, Budapest, Hungary
| | - George Follows
- Cambridge University Hospitals, Cambridge, United Kingdom
| | - Georg Lenz
- Translational Oncology Medical Clinic, Münster University Clinic, Münster, Germany
| | - Won Seog Kim
- Sungkyunkwan University School of Medicine, Samsung Medical Center, Division of Hematology and Oncology, Seoul, Republic of Korea
| | | | - Arnon Nagler
- Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel
| | - Colin Phipps Diong
- Singapore General Hospital, Department of Haematology, Singapore, Singapore
| | - Mariano Provencio
- Health Research Institute, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, Madrid, Spain
| | | | - David Trevarthen
- Comprehensive Cancer Care and Research Institute of Colorado, Englewood, CO
| | - Massimo Magagnoli
- Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - Lisa Cupit
- Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
| | - Shuxin Yin
- Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ
| | | | | | | | - Pier Luigi Zinzani
- Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy
| |
Collapse
|
4
|
Liu LI, Koechert K, Cheng J, Garcia-Vargas JE, Childs BH, Dreyling MH, Pena CE. Association of activated BCR and PI3K pathways with responses and longer PFS to single-agent copanlisib in heavily pretreated patients with indolent and aggressive NHL. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e19063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- LI Liu
- Bayer HealthCare Pharmaceuticals, Whippany, NJ
| | | | | | | | | | - Martin H. Dreyling
- Medizinische Klinik und Poliklinik III Klinikum der Universität München, München, Germany
| | | |
Collapse
|
5
|
Morris MJ, Higano CS, Scher HI, Sweeney C, Antonarakis ES, Shevrin DH, Ryan CJ, Loriot Y, Fizazi K, Pandit-Taskar N, Garcia-Vargas JE, Lyseng K, Bloma M, Carrasquillo JA. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.5012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Celestia S. Higano
- University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA
| | | | | | | | - Daniel H. Shevrin
- NorthShore University Health System, Evanston Hospital Kellogg Cancer Center, Evanston, IL
| | - Charles J. Ryan
- UC San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Yohann Loriot
- Institut Gustave-Roussy, Departement de Medecine Oncologique, University of Paris Sud, Villejuif, France
| | - Karim Fizazi
- Institut Gustave-Roussy, Departement de Medecine Oncologique, University of Paris Sud, Villejuif, France
| | | | | | - Kari Lyseng
- Bayer AS (formerly Algeta ASA), Oslo, Norway
| | | | | |
Collapse
|
6
|
Morris MJ, Higano CS, Scher HI, Sweeney C, Antonarakis ES, Shevrin DH, Ryan CJ, Loriot Y, Fizazi K, Pandit-Taskar N, Garcia-Vargas JE, Lyseng K, Bloma M, Aksnes AK, Carrasquillo JA. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.7_suppl.202] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
202 Background: Ra-223 is an approved α-emitter prolonging survival in CRPC with symptomatic bone mets. We conducted a phase 1/2a study examining the safety and antitumor effects of Ra-223 + D vs D alone, and previously presented data showing that Ra-223 + D is safe and well tolerated (ESMO 2014). Here we report the effect of Ra-223 + D vs D on bALP and PSA dynamics. Methods: D-eligible pts with progressing CRPC and ≥ 2 bone mets were randomized 2:1 to Ra-223 (50 kBq/kg q 6 wk × 5) + D (60 mg/m2 q 3 wk × 10) vs D (75 mg/m2 q 3 wk with step-down option to 60 mg/m2). bALP and PSA were recorded q 3 wk during first 6-wk cycle, then q 6 wk and q 3 wk, respectively, and analyzed at a central laboratory. Changes in both markers are described by the % of pts who achieved ≥ 30%, > 50%, and > 80% declines between baseline and the safety follow-up visit (3 wk post last D injection) as their best response; pts with elevated baseline bALP (≥ 21 µg/L) levels were included for the bALP analysis. bALP to below the upper limit of normal (ULN) was also recorded, regardless of % decline. Results: 46 pts (33 Ra-223 + D vs 13 D alone) were enrolled. As of October 2014, 21 (Ra-223 + D) vs 5 (D) pts had received all planned study treatment. Median (range) baseline PSA was 99 µg/L (3-1000) for Ra-223 + D pts and 43 µg/L (4-1042) for D pts. Maximal changes in PSA and bALP levels between baseline and safety follow-up are shown in Table. No pt had a bALP increase. Conclusions: Ra-223 + D appears to favorably impact posttreatment PSA and bALP declines. Ra-223 + D appears particularly effective at normalizing bALP levels vs D alone. The clinical benefits of such changes in serum markers will require validation in larger prospective studies. Clinical trial information: NCT01106352. [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | - Charles J. Ryan
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
| | - Yohann Loriot
- Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Karim Fizazi
- Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | | | | | | | | | | | | |
Collapse
|
7
|
Finkelstein SE, Michalski JM, O'Sullivan JM, Parker C, Garcia-Vargas JE, Sartor AO. External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.7_suppl.182] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
182 Background: In ALSYMPCA, Ra-223, a first-in-class α-emitter, improved overall survival and delayed time to first symptomatic skeletal event vs placebo (pbo). This post hoc analysis evaluated safety and efficacy of Ra-223 plus EBRT. Methods: Pts had symptomatic (recent EBRT for bone pain or any regular analgesic use) CRPC with ≥ 2 bone and no visceral mets; best standard of care; and prior docetaxel (pD) or were unfit for or declined docetaxel (no pD). Pts were stratified by pD use (yes/no), baseline total alkaline phosphatase level (tALP; < 220 U/L or ≥ 220 U/L), and current bisphosphonate (bp) use (yes/no) and randomized 2:1 to 6 Ra-223 injections (50 kBq/kg IV q 4 wk) or pbo. EBRT for bone pain was permitted within 12 weeks prior to randomization and during study. Baseline pain by prior EBRT, time to first on-study EBRT use for bone pain, and adverse events (AEs) by concomitant EBRT (cEBRT) were analyzed. Results: Pts with no prior EBRT had less pain at baseline; a WHO pain score ≤ 1 (no opioid use) was present in 46% (355/724) of pts with no prior EBRT vs 36% (53/147) of pts with prior EBRT. Ra-223 vs pbo significantly reduced EBRT use in the overall population (HR = 0.67, P = 0.001) and in pts with ≤ 20 bone mets (HR = 0.49, P < 0.001), current bp use (HR = 0.47, P = 0.004), tALP < 220 U/L (HR = 0.66, P = 0.008), and no pD (HR = 0.65, P = 0.038). At 6 months, the percentage of Ra-223 pts requiring EBRT was similar for prior and no prior EBRT subgroups (24% vs 20%), increasing at 12 months (38% vs 29%). cEBRT did not affect Ra-223 safety, and myelosuppression was low (Table). Conclusions: cEBRT did not adversely affect Ra-223 hematologic safety. Ra-223 significantly reduced risk of EBRT use. In Ra-223 pts, prior EBRT did not appear to affect later EBRT use. Clinical trial information: NCT00699751. [Table: see text]
Collapse
Affiliation(s)
| | - Jeff M. Michalski
- Washington University School of Medicine in St. Louis, St. Louis, MO
| | - Joe M. O'Sullivan
- Centre for Cancer Research and Cell Biology, Queen's University, Belfast, United Kingdom
| | - Chris Parker
- The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom
| | | | | |
Collapse
|
8
|
Sartor AO, Amariglio R, Wilhelm S, Garcia-Vargas JE, O'Bryan-Tear CG, Shan M, Fang F, Parker C. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.5080] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5080 Background: In patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC), total ALP (tALP) has been shown to be a prognostic marker for overall survival (OS) (Cook 2006). Here the prognostic value of tALP and other baseline clinical variables in Ra-223 pts is presented, along with the initial results of an exploratory analysis of changes in tALP seen with Ra-223. Methods: Study population included 921 pts (intent-to-treat population) from the ALSYMPCA trial. The Cox proportional hazards model was used to evaluate the prognostic potential of tALP and other baseline variables (albumin, Hb, LDH, ECOG performance status, PSA, and age). Log transformation was done for baseline variables (tALP, PSA, and LDH) with heavily skewed distributions. Baseline variables were assessed for interaction with treatment. To determine changes in tALP from baseline at 12 wk, 708 pts who had tALP measurements at both baseline and 12 wk were included. Results: The baseline variables in the Table were significantly associated with OS. Hb was not a significant factor when adjusting for all other covariates and was therefore removed from the final Cox regression model. No significant treatment-by-covariate interactions were detected. After controlling for other variables, higher baseline tALP was significantly associated with an increased risk of death (p < 0.0001). At 12 wk, a decline in tALP relative to baseline was seen in 87% (433/497) of Ra-223 pts, compared to 23% (49/211) of placebo pts. The mean percentage change from baseline in tALP at 12 wk was a 32% decline for Ra-223 pts, in contrast to a 37% increase for placebo pts (p< 0.001). Conclusions: In mCRPC pts, higher baseline levels of tALP were associated with an increased risk of death. With the majority of Ra-223 pts experiencing a decline in tALP at 12 wk, and the marked mean percentage tALP decline in these pts, further analysis to determine a correlation between tALP dynamics and survival is warranted. Clinical trial information: NCT00699751. [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | - Fang Fang
- Bayer HealthCare Pharmaceuticals, Montville, NJ
| | - Chris Parker
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| |
Collapse
|
9
|
Parker C, Garcia-Vargas JE, O'Bryan-Tear CG, Fang F, Vogelzang NJ. Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.5060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5060 Background: In the updated analysis of the ALSYMPCA study, Ra-223 significantly improved median survival by 3.6 mo vs placebo (Pbo) in 921 CRPC patients (pts) with bone mets (HR = 0.695; 95% CI, 0.581-0.832; p = 0.00007) and had a highly favorable safety profile (Parker et al. ASCO 2012). The hematologic safety profile and results from a post hoc analysis assessing prognostic factors for changes in hematologic parameters in ALSYMPCA pts are presented. Methods: Pts were randomized 2:1 to 6 injections (inj) of Ra-223 (50 kBq/kg IV) q4wk or matching Pbo and stratified by prior docetaxel (D) use, total alkaline phosphatase (tALP), and current bisphosphonate use.Multivariate regression analysis was performed to explore the relationship of 6 baseline factors (Table) with maximum % change of hematologic parameters from baseline up to 24 wk on treatment (tx). Results: The updated analysis included 901 pts (safety population; Ra-223, n = 600; Pbo, n = 301). Overall grade 3/4 AEs were similar between Ra-223 and Pbo groups, with neutropenia in 2% and 1%, thrombocytopenia in 6% and 2%, and anemia in 13% and 13% of Ra-223 and Pbo groups, respectively. Tx with Ra-223, prior D use, extent of disease (EOD) > 6 bone mets, and tALP ≥ 220 U/L, but not current bisphosphonate use, were associated with decreases from baseline in hemoglobin (Hb), neutrophils, or platelets; prior EBRT to bone for pain was associated with an increase. The significance of the relationship between baseline factors and changes in hematologic parameters is summarized in the Table. Conclusions: Overall, there was a low risk for hematologic AEs with Ra-223 tx in CRPC pts with bone mets. The strongest prognostic factors for decreases in neutrophils and platelets were Ra-223 tx and prior D use. Baseline tALP ≥ 220 U/L was a strong predictor of decrease in Hb. Clinical trial information: NCT00699751. [Table: see text]
Collapse
Affiliation(s)
- Chris Parker
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | | | | | - Fang Fang
- Bayer HealthCare Pharmaceuticals, Montville, NJ
| | | |
Collapse
|
10
|
Vogelzang NJ, Helle SI, Johannessen DC, O'Sullivan JM, Garcia-Vargas JE, O'Bryan-Tear CG, Shan M, Parker C. Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.5068] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5068 Background: Ra-223, a first-in-class α-emitter, significantly improved median overall survival (OS) by 3.6 mo vs placebo (Pbo) in CRPC patients (pts) with bone metastases (mets) receiving best standard of care (BSoC) in the ALSYMPCA study (HR = 0.695; 95% CI, 0.581-0.832; p = 0.00007), and had a highly favorable safety profile in the updated ALSYMPCA analysis (Parker et al. ASCO 2012). This predefined subgroup analysis assessed efficacy and safety of Ra-223 in pts who did or did not receive prior D (pD). Methods: Eligible pts had progressive, symptomatic CRPC with ≥ 2 bone mets; had no known visceral mets; were receiving BSoC; and had received pD, or were unfit for or declined D (npD). Pts were randomized 2:1 to 6 injections of Ra-223 (50 kBq/kg IV) q4wk or matching Pbo and stratified by prior D use, baseline alkaline phosphatase level, and current bisphosphonate use. Survival data were compared using a log-rank test. Results: 395/921 (43%) randomized pts had npD (Ra-223, n = 262; Pbo, n = 133); 526/921 (57%) received pD (Ra-223, n = 352; Pbo, n = 174). Median ages were 74 y (npD) and 69 y (pD). In pts with npD, median OS was 16.1 mo in the Ra-223 group vs 11.5 mo in the Pbo group (HR = 0.745; 95% CI, 0.562-0.987; p = 0.039). In pts with pD, median OS was 14.4 mo vs 11.3 mo in the Ra-223 and Pbo groups, respectively (HR = 0.710; 95% CI, 0.565-0.891; p = 0.003). Overall, there was a low incidence of myelosuppression. Incidences of neutropenia and thrombocytopenia were higher in pts with pD vs pts with npD. Conclusions: Ra-223 significantly prolonged OS and had a highly favorable safety profile in CRPC pts with bone mets, regardless of whether they had pD or npD. pD pts had a slightly increased rate of grade 3 and 4 bone marrow suppression with Ra-223. Clinical trial information: NCT00699751. [Table: see text]
Collapse
Affiliation(s)
| | | | | | - Joe M. O'Sullivan
- Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland
| | | | | | | | - Chris Parker
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| |
Collapse
|
11
|
Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, Coleman RE, Vogelzang NJ, O'Bryan-Tear CG, Garcia-Vargas JE, Shan M, Sartor AO. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.18_suppl.lba4512] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA4512 Background: Radium-223 chloride (Ra-223), a targeted alpha-emitter, targets bone metastases (mets) with high-energy alpha-particles of short range (<100 µm). ALSYMPCA, a phase III double-blind, randomized, multinational study, compared Ra-223 plus best standard of care (BSC) vs placebo plus BSC in CRPC patients (pts) with bone mets. In a planned interim analysis (n = 809), based on 314 events, Ra-223 significantly improved overall survival (OS) vs placebo (median 14.0 mo vs 11.2 mo, respectively; HR = .695; 95% CI, .552-.875; 2-sided p = .00185). Secondary endpoints were met and Ra-223 safety was favorable. An updated analysis was conducted prior to the crossover to further assess the effect of Ra-223 on the primary endpoint (OS), secondary endpoints including skeletal-related events (SREs), and safety. Methods: Eligible pts had confirmed symptomatic CRPC with ≥ 2 bone mets; no known visceral mets; and were post-docetaxel, unfit for docetaxel, or had declined docetaxel. Pts were randomized 2:1 to receive 6 injections of Ra-223 (50 kBq/kg IV) q4wks or matching placebo. An updated descriptive analysis of OS, based on 528 events, was performed including data from all randomized pts prior to implementing crossover to Ra-223 for placebo pts. Results: 921 pts (Ra-223, n = 614; placebo, n = 307) were randomized from 6/2008-2/2011. Ra‑223 significantly improved OS vs placebo (median 14.9 mo vs 11.3 mo, respectively; HR = .695; 95% CI, .581-.832; p = 0.00007), and time to first SRE was significantly prolonged (median 15.6 mo vs 9.8 mo, respectively; HR = 0.658; 95% CI, 0.522-0.830; p = 0.00037). Safety and tolerability of Ra-223 remained favorable, with low myelosuppression (e.g., gr 3/4 neutropenia in 2.2% and 0.7% and gr 3/4 thrombocytopenia in 6.3% and 2% of the Ra-223 and placebo groups, respectively). Conclusions: On updated analysis, the median OS benefit for Ra-223 increased from 2.8 to 3.6 months, with a hazard ratio of 0.695 (i.e., 30.5% reduction in risk of death). Ra-223 is an effective therapy that improves OS and time to first SRE with a highly favorable safety profile, and may provide a new standard of care for CRPC pts with bone mets.
Collapse
Affiliation(s)
- Chris Parker
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Sten Nilsson
- Karolinska University Hospital, Stockholm, Sweden
| | | | - Joe M. O'Sullivan
- Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland
| | | | | | - Pawel J. Wiechno
- Centrum Onkologii – Instytut im Sklodowskiej-Curie, Warsaw, Poland
| | | | | | | | | | - Peter Hoskin
- Mount Vernon Hospital Cancer Centre, Middlesex, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Sartor AO, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A, Johannessen DC, Nilsson S, Hoskin P, Bottomley D, Coleman RE, Vogelzang NJ, O'Bryan-Tear CG, Garcia-Vargas JE, Shan M, Parker C. Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.4551] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4551 Background: Ra-223, a 1st-in-class alpha-pharmaceutical, targets bone metastases (mets) with high-energy alpha-particles of short range (<100 μm). ALSYMPCA, a phase III, double-blind, randomized, multinational study, compared Ra-223 plus best standard of care (BSC) v placebo (pbo) plus BSC in patients (pts) with bone mets in CRPC. The primary endpoint was OS; secondary endpoints included SREs and ECOG PS. Methods: Eligible pts had progressive, symptomatic CRPC with ≥ 2 bone mets on scintigraphy and no known visceral mets; were receiving BSC; and either previously received docetaxel, were docetaxel ineligible, or refused docetaxel. Pts were randomized 2:1 to 6 injections of Ra‑223 (50 kBq/kg IV) q4 wks or matching pbo and stratified by prior docetaxel use, baseline ALP level, and current bisphosphonate use. Results: 921 pts were randomized from 6/2008-2/2011. In a planned interim analysis (n = 809), Ra-223 significantly improved OS v pbo (median OS 14.0 v 11.2 mo, respectively; two-sided P = .00185; HR = .695; 95% CI, .552-.875).SREs were lower in the Ra-223 v pbo group, and time to 1st SRE was significantly delayed (median time to SRE 13.6 mo v 8.4 mo, respectively; P = .00046; HR = .610; 95% CI, .461-.807). The proportion of pts with ECOG PS deterioration (≥ 2 points) was less in Ra-223 v pbo group at Wk 12 and Wk 24 (4%, 15/389 v 9%, 16/180 and 7%, 16/236 v 12%, 10/83, respectively). Time to ECOG PS deterioration (≥ 2 points) was significantly delayed by Ra-223 v pbo (P = .003; HR = .62; 95% CI, .46-.85). Conclusions: Ra-233 significantly delayed time to 1st SRE and SRE components, notably SCC. Fewer pts in the Ra-223 group had ECOG PS deterioration. Ra-223 improves OS with excellent safety and may provide a new standard of care for CRPC pts with bone mets. [Table: see text]
Collapse
Affiliation(s)
| | | | - Joe M. O'Sullivan
- Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland
| | | | | | - Pawel J. Wiechno
- Centrum Onkologii – Instytut im Sklodowskiej-Curie, Warsaw, Poland
| | | | | | | | | | - Sten Nilsson
- Karolinska Universitettsjukhuset, Stockholm, Sweden
| | - Peter Hoskin
- Mount Vernon Hospital Cancer Centre, Middlesex, United Kingdom
| | | | | | | | | | | | | | - Chris Parker
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| |
Collapse
|
13
|
Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno PJ, Logue JP, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, Coleman RE, Vogelzang NJ, O'Bryan-Tear CG, Garcia-Vargas JE, Shan M, Sartor AO. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.lba4512] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA4512 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
Collapse
Affiliation(s)
- Chris Parker
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Sten Nilsson
- Karolinska University Hospital, Stockholm, Sweden
| | | | - Joe M. O'Sullivan
- Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland
| | | | | | - Pawel J. Wiechno
- Centrum Onkologii – Instytut im Sklodowskiej-Curie, Warsaw, Poland
| | | | | | | | | | - Peter Hoskin
- Mount Vernon Hospital Cancer Centre, Middlesex, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Parker C, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Demkow T, Logue JP, Seke M, Widmark A, Johannessen DC, Nilsson S, Hoskin P, Solberg A, James ND, Syndikus I, Cross A, O'Bryan-Tear CG, Garcia-Vargas JE, Sartor AO. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.5_suppl.8] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8 Background: Radium-223 chloride (Ra-223) is a first-in-class alpha-pharmaceutical targeting bone metastases (mets) with high-energy alpha-particles of extremely short range (<100 μm). ALSYMPCA, a phase III, double-blind, randomized, multinational study, compared efficacy, in terms of overall survival (OS), and safety of Ra-223 plus best standard of care (BSC) vs placebo plus BSC in patients (pts) with bone mets in CRPC. Methods: Eligible pts had progressive, symptomatic CRPC with ≥ 2 bone mets on scintigraphy and no known visceral mets; were receiving BSC; and either previously received docetaxel, were docetaxel ineligible, or refused docetaxel. Pts were randomized 2:1 to receive 6 injections of Ra‐223 (50 kBq/kg IV) q4 wks or matching placebo and stratified by prior docetaxel use, baseline alkaline phosphatase level, and current bisphosphonate use. A planned interim analysis (IA) was conducted to assess the effect of Ra-223 on the primary endpoint (OS) using a predefined threshold. Survival data were compared using a stratified log-rank test. Results: 922 pts (Ra-223, n = 615; placebo, n = 307) were randomized from 6/2008-2/2011. 445 (58%) of 809 pts in the IA data set received prior treatment with docetaxel. Ra-223 significantly improved OS in pts with CRPC with bone mets vs placebo (two-sided P = 0.00185; HR = 0.695; 95% CI, 0.552-0.875; median OS 14.0 mo vs 11.2 mo, respectively). Safety and tolerability of Ra-223 were highly favorable and showed low incidence of myelosuppression (eg, grades 3/4 neutropenia in 1.8% and 0.8% and thrombocytopenia in 4% and 2% of the Ra-223 and placebo groups, respectively). Conclusions: Ra-223 is an effective therapy that improved OS with a highly favorable safety profile, and may provide a new standard of care for the treatment of CRPC pts with bone mets. [Table: see text]
Collapse
Affiliation(s)
- Chris Parker
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Daniel Heinrich
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Joe M. O'Sullivan
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Sophie D. Fossa
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Ales Chodacki
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Tomasz Demkow
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - John P. Logue
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Mihalj Seke
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Anders Widmark
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Dag Clement Johannessen
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Sten Nilsson
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Peter Hoskin
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Arne Solberg
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Nicholas David James
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Isabel Syndikus
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Andrew Cross
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - C. Gillies O'Bryan-Tear
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - Jose E. Garcia-Vargas
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| | - A. Oliver Sartor
- The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Akershus University Hospital, Lorenskog, Norway; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, Ireland; Radiumhospitalet, Oslo, Norway; Hospital Kochova, Chomutov, Czech Republic; Centrum Onkologii-Instytut im Sklodowskiej-Curie, Warsaw, Poland; Christie Hospital, Manchester, United Kingdom; Centrallasarettet Växjö, Växjö, Sweden; Norrlands University Hospital, Umeå, Sweden; Ullevål University Hospital, Oslo,
| |
Collapse
|
15
|
Gambacorta MA, Valentini V, Coco C, Morganti AG, Smaniotto D, Miccichè F, Mantini G, Barbaro B, Garcia-Vargas JE, Magistrelli P, Picciocchi A, Cellini N. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies. Int J Radiat Oncol Biol Phys 2004; 60:139-48. [PMID: 15337549 DOI: 10.1016/j.ijrobp.2004.01.051] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2003] [Revised: 01/23/2004] [Accepted: 01/26/2004] [Indexed: 11/22/2022]
Abstract
PURPOSE Two separate studies were conducted, the first to evaluate the maximal tolerated dose and the second the efficacy of raltitrexed plus oxaliplatin in conjunction with preoperative chemoradiation in patients with resectable T3 rectal carcinoma. METHODS AND MATERIALS A total of 48 patients received radiotherapy (50 Gy) administered to the posterior pelvis 5 d/wk for 5 weeks. Combination raltitrexed (3 mg/m(2)) and oxaliplatin (60 to 130 mg/m(2)) was administered on Days 1, 19, and 38. RESULTS The recommended dose of oxaliplatin is 130 mg/m(2) (maximal tolerated dose not reached). No patients developed Grade 4 acute toxicity. Grade 3 acute toxicity occurred in 9 patients (18.7%). It was hematologic in 1 patient and GI in 1 patient; 7 patients had an asymptomatic increase of transaminase. Surgery was performed in 47 (98%) of 48 patients. Of the 47 patients, 42 underwent sphincter-saving surgery; in 19, the tumor at diagnosis was located <30 mm from the anorectal ring. Chemoradiation in combination with raltitrexed and oxaliplatin produced high rates of tumor response. The overall tumor downstaging rate was 73% for T and N stages. A complete pathologic tumor response (pT0) or microscopic tumor foci (pTmic) was observed in 28 patients. The tumor regression grade (TRG), using the Mandard scoring system, was TRG1 in 16 patients (43.2%), TRG2 in 12 (32.4%), TRG3 in 12 (32.4%), TRG4 in 6 (16.2%), and TRG5 in 1 patient (2.7%). CONCLUSION Raltitrexed plus oxaliplatin combined with pelvic radiotherapy was effective and well tolerated in patients with resectable T3 rectal carcinoma.
Collapse
Affiliation(s)
- Maria Antonietta Gambacorta
- Department of Radiation Therapy, Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, Largo A. Gemelli 8, Rome 00168, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Koehler M, Garcia-Vargas JE, O'Dwyer PJ. Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. Cancer Chemother Pharmacol 2004; 53:357-60. [PMID: 14722734 DOI: 10.1007/s00280-003-0735-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2003] [Accepted: 10/03/2003] [Indexed: 11/25/2022]
Abstract
PURPOSE To determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of ZD9331 in combination with cisplatin in patients with refractory solid tumors and to describe any preliminary antitumor activity associated with this regimen. MATERIALS AND METHODS Patients received combination therapy with ZD9331 as a 30-min infusion on days 1 and 8 of a 21-day cycle at doses of 100 or 130 mg/m(2), followed by cisplatin at 50 or 75 mg/m(2) as a 30- to 60-min infusion on day 1 only. RESULTS A total of 16 patients received 59 cycles of ZD9331 and cisplatin. Patients were enrolled at three dose levels: ZD9331/cisplatin 100/50 ( n=3), 130/50 ( n=9), 130/75 ( n=4). DLTs at 130/75 included thrombocytopenia, neutropenia, fatigue, nausea, vomiting and stomatitis. Among 15 evaluable patients, 2 showed a partial response (patients with mesothelioma and head and neck cancer) and 6 showed stable disease (for a median of 5.5 cycles). CONCLUSIONS ZD9331 in combination with cisplatin was well tolerated at a dose of 130/50 mg/m(2) after establishing the principal DLTs of neutropenia and thrombocytopenia. The combination shows evidence of antitumor activity in a pretreated population.
Collapse
Affiliation(s)
- Joshua H Bilenker
- Abramson Family Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|